glp 1 agonist vs sglt2 inhibitor Disparities in or Glucagon-Like Peptide Receptor Initiation Among Medicare-Insured Adults With CKD in the United States SGLT2 Inhibitors and GLP-1 Receptor

Based on this evidence, it is recommended that long-term pharmacological management prioritize the optimization of treatment timing, formulation of personalized dosing regimens, and implementation of systematic efficacy monitoring and adverse reaction assessment protocols, to maximize therapeutic benefits while minimizing potential risks

Earlier versions of GLP-1 drugs, such as exenatide (Byetta), increased the risk for pancreatic cancer or certain types of thyroid cancer and even instances of autoimmunity

10.1210/en.2014-1978 74 PerkovicV.TuttleK

Dietary composition significantly influences GLP-1 secretion, with specific macronutrients and food components demonstrating particular efficacy

Looking at the global market, GLP-1RA has steadily increased its share in the market of hypoglycemic drugs